8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Mar 12, 2026·SEC
Avanos Medical, Inc.(AVNS)Earnings, Financials & Key Ratios
AVNS•NYSE
Price updated Jun 19, 2026
AboutAvanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Show more
- Revenue$701M+1.9%
- EBITDA-$33M-138.1%
- Net Income-$68M+82.7%
- EPS (Diluted)-1.46+82.9%
- Gross Margin49.77%-10.2%
- EBITDA Margin-4.65%-137.4%
- Operating Margin-8.78%-251.1%
- Net Margin-9.68%+83.0%
- ROE-8.45%+77.7%
AVNS Key Insights
Avanos Medical, Inc. (AVNS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓Trading near 52-week high
- ✓Trading at only 1.5x book value
✗Weaknesses
- ✗Profits declining 20.1% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AVNS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVNS Price & Volume
Avanos Medical, Inc. (AVNS) stock price & volume — 10-year historical chart
Loading chart...
AVNS Growth Metrics
Avanos Medical, Inc. (AVNS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.77%
5 Years-0.38%
3 Years0.83%
TTM3.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM81.96%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM82.07%
Return on Capital
10 Years1.1%
5 Years1.92%
3 Years0.34%
Last Year-6.5%
AVNS Recent Earnings
Avanos Medical, Inc. (AVNS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.22+37.5%
$0.16
Rev
$182M+7.2%
$170M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.29+20.8%
$0.24
Rev
$181M+3.5%
$175M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.22+83.3%
$0.12
Rev
$178M+8.1%
$165M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.17-5.6%
$0.18
Rev
$175M+4.5%
$168M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.22vs $0.16+37.5% | $182Mvs $170M+7.2% |
| Q1 2026 | Feb 24, 2026 | $0.29vs $0.24+20.8% | $181Mvs $175M+3.5% |
| Q4 2025 | Nov 5, 2025 | $0.22vs $0.12+83.3% | $178Mvs $165M+8.1% |
| Q3 2025 | Aug 5, 2025 | $0.17vs $0.18-5.6% | $175Mvs $168M+4.5% |
Based on last 12 quarters of dataView full earnings history →
AVNS Peer Comparison
Avanos Medical, Inc. (AVNS) competitors in Respiratory and sleep therapy devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 ICUI | 3.51B | 140.37 | 4774.49 | -6.38% | 2.15% | 2.19% | 0.66 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% |
Compare AVNS vs Peers
Avanos Medical, Inc. (AVNS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVNS Income Statement
Avanos Medical, Inc. (AVNS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 611.6M | 652.3M | 697.6M | 714.8M | 744.6M | 684.1M | 673.3M | 687.8M | 701.2M | 715.9M |
Revenue Growth % | 8.02% | 6.65% | 6.94% | 2.47% | 4.17% | -8.13% | -1.58% | 2.15% | 1.95% | 3.87% |
Cost of Goods Sold | 274.7M | 261.4M | 295.4M | 324.2M | 364.7M | 289.9M | 293.6M | 306.5M | 352.2M | 362.5M |
COGS % of Revenue | 44.91% | 40.07% | 42.35% | 45.36% | 48.98% | 42.38% | 43.61% | 44.56% | 50.23% | - |
Gross Profit | 336.9M▲ 0% | 390.9M▲ 16.0% | 402.2M▲ 2.9% | 390.6M▼ 2.9% | 379.9M▼ 2.7% | 394.2M▲ 3.8% | 379.7M▼ 3.7% | 381.3M▲ 0.4% | 349M▼ 8.5% | 353.4M▲ 0% |
Gross Margin % | 55.08% | 59.93% | 57.65% | 54.64% | 51.02% | 57.62% | 56.39% | 55.44% | 49.77% | 49.36% |
Gross Profit Growth % | 13.36% | 16.03% | 2.89% | -2.88% | -2.74% | 3.76% | -3.68% | 0.42% | -8.47% | - |
Operating Expenses | 352.9M | 356M | 407.6M | 319.7M | 293.1M | 352.3M | 314.7M | 341.3M | 410.6M | 333.3M |
OpEx % of Revenue | 57.7% | 54.58% | 58.43% | 44.73% | 39.36% | 51.5% | 46.74% | 49.62% | 58.56% | - |
Selling, General & Admin | 314.7M | 314.2M | 369.9M | 284.8M | 260.8M | 323.1M | 287.5M | 315.1M | 218.3M | 218.9M |
SG&A % of Revenue | 51.46% | 48.17% | 53.02% | 39.84% | 35.03% | 47.23% | 42.7% | 45.81% | 31.13% | - |
Research & Development | 38.2M | 41.8M | 37.7M | 34.9M | 32.3M | 30.6M | 27.2M | 26.2M | 23.1M | 22.9M |
R&D % of Revenue | 6.25% | 6.41% | 5.4% | 4.88% | 4.34% | 4.47% | 4.04% | 3.81% | 3.29% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 169.2M | 1000K |
Operating Income | -16M▲ 0% | 34.9M▲ 318.1% | -5.4M▼ 115.5% | 70.9M▲ 1413.0% | 86.8M▲ 22.4% | 41.9M▼ 51.7% | 65M▲ 55.1% | 40M▼ 38.5% | -61.6M▼ 254.0% | -60M▲ 0% |
Operating Margin % | -2.62% | 5.35% | -0.77% | 9.92% | 11.66% | 6.12% | 9.65% | 5.82% | -8.78% | -8.38% |
Operating Income Growth % | 76.95% | 318.13% | -115.47% | 1412.96% | 22.43% | -51.73% | 55.13% | -38.46% | -254% | - |
EBITDA | 24M | 68.4M | 31.5M | 113.8M | 125.1M | 83M | 108.5M | 85.5M | -32.6M | -20.5M |
EBITDA Margin % | 3.92% | 10.49% | 4.52% | 15.92% | 16.8% | 12.13% | 16.11% | 12.43% | -4.65% | -2.86% |
EBITDA Growth % | 184.51% | 185% | -53.95% | 261.27% | 9.93% | -33.65% | 30.72% | -21.2% | -138.13% | -121.29% |
D&A (Non-Cash Add-back) | 40M | 33.5M | 36.9M | 42.9M | 38.3M | 41.1M | 43.5M | 45.5M | 29M | 39.5M |
EBIT | -40.6M | 3.5M | -49M | -44.9M | 10.6M | 36.7M | 7.1M | -391.1M | -62.2M | -70.2M |
Net Interest Income | -29.1M | -18.6M | -8.3M | -14.4M | -3.1M | -8.8M | -12.1M | -7.1M | -800K | -4M |
Interest Income | 2.5M | 7.8M | 6.7M | 1.2M | 200K | 1.2M | 2.9M | 5.1M | 3.2M | 1.9M |
Interest Expense | 31.6M | 26.4M | 15M | 15.6M | 3.3M | 10M | 15M | 12.2M | 4M | 4.2M |
Other Income/Expense | -56.2M | -53M | -58.6M | -131.4M | -79.5M | -15.2M | -72.9M | -443.3M | -4.6M | -8.3M |
Pretax Income | -72.2M▲ 0% | -18.1M▲ 74.9% | -64M▼ 253.6% | -60.5M▲ 5.5% | 7.3M▲ 112.1% | 26.7M▲ 265.8% | -7.9M▼ 129.6% | -403.3M▼ 5005.1% | -66.2M▲ 83.6% | -68.3M▲ 0% |
Pretax Margin % | -11.81% | -2.77% | -9.17% | -8.46% | 0.98% | 3.9% | -1.17% | -58.64% | -9.44% | -9.54% |
Income Tax | -40.1M | -9.6M | -18.1M | -33.3M | 1M | 5.2M | 2M | -17M | 1.7M | -3.9M |
Effective Tax Rate % | 55.54% | 53.04% | 28.28% | 55.04% | 13.7% | 19.48% | -25.32% | 4.22% | -2.57% | 5.71% |
Net Income | 79.3M▲ 0% | 57.5M▼ 27.5% | -45.9M▼ 179.8% | -27.2M▲ 40.7% | 6.3M▲ 123.2% | 50.5M▲ 701.6% | -61.8M▼ 222.4% | -392.1M▼ 534.5% | -67.9M▲ 82.7% | -69.4M▲ 0% |
Net Margin % | 12.97% | 8.82% | -6.58% | -3.81% | 0.85% | 7.38% | -9.18% | -57.01% | -9.68% | -9.69% |
Net Income Growth % | 99.25% | -27.49% | -179.83% | 40.74% | 123.16% | 701.59% | -222.38% | -534.47% | 82.68% | 81.96% |
Net Income (Continuing) | -32.1M | -8.5M | -45.9M | -27.2M | 6.3M | 21.5M | -9.9M | -386.3M | -67.9M | -69.4M |
Discontinued Operations | 111.4M | 66M | 0 | 0 | 0 | 29M | -51.9M | -5.8M | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.69▲ 0% | 1.22▼ 27.8% | -0.96▼ 178.7% | -0.57▲ 40.6% | 0.13▲ 122.8% | 1.07▲ 723.1% | -1.33▼ 224.3% | -8.53▼ 541.4% | -1.46▲ 82.9% | -1.50▲ 0% |
EPS Growth % | 98.82% | -27.81% | -178.69% | 40.63% | 122.81% | 723.08% | -224.3% | -541.35% | 82.88% | 82.07% |
EPS (Basic) | 1.69 | 1.22 | -0.96 | -0.57 | 0.13 | 1.08 | -1.33 | -8.53 | -1.46 | - |
Diluted Shares Outstanding | 46.8M | 47.2M | 47.6M | 47.8M | 48.6M | 47.3M | 46.6M | 46M | 46.4M | 46.4M |
Basic Shares Outstanding | 46.52M | 47.2M | 47.6M | 47.8M | 48.1M | 46.9M | 46.6M | 46M | 46.4M | 46.4M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AVNS Balance Sheet
Avanos Medical, Inc. (AVNS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.16B | 713.6M | 538.5M | 467.2M | 427.6M | 624.1M | 487M | 393.4M | 355.4M | 325M |
Cash & Short-Term Investments | 219.7M | 384.5M | 205.3M | 111.5M | 118.5M | 127.7M | 87.7M | 107.7M | 89.8M | 65.6M |
Cash Only | 219.7M | 384.5M | 205.3M | 111.5M | 118.5M | 127.7M | 87.7M | 107.7M | 89.8M | 65.6M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 203M | 150.5M | 163.8M | 167.9M | 131.2M | 167.9M | 142.8M | 132.8M | 103.8M | 103M |
Days Sales Outstanding | 121.15 | 84.21 | 85.7 | 85.74 | 64.31 | 89.58 | 77.41 | 70.47 | 54.03 | 54.59 |
Inventory | 91.1M | 121.4M | 145.9M | 168.9M | 159.3M | 132.3M | 163.2M | 138.8M | 148M | 141.3M |
Days Inventory Outstanding | 121.05 | 169.51 | 180.28 | 190.16 | 159.43 | 166.57 | 202.89 | 165.29 | 153.38 | 146.65 |
Other Current Assets | 632.5M | 57.2M | 0 | 0 | 0 | 196.2M | 93.3M | 14.1M | 13.8M | 15.1M |
Total Non-Current Assets | 1.04B | 1.12B | 1.26B | 1.21B | 1.18B | 1.16B | 1.21B | 760.8M | 718.3M | 725.1M |
Property, Plant & Equipment | 109.9M | 154.1M | 248.5M | 223.6M | 206.7M | 146.1M | 144M | 144.8M | 141M | 150.5M |
Fixed Asset Turnover | 5.57x | 4.23x | 2.81x | 3.20x | 3.60x | 4.68x | 4.68x | 4.75x | 4.97x | 4.92x |
Goodwill | 764.7M | 783.6M | 800.9M | 802.5M | 801.6M | 760.3M | 796.1M | 455.6M | 394.9M | 394M |
Intangible Assets | 148.9M | 168.2M | 184.3M | 157.7M | 141.2M | 234.2M | 239.5M | 112.3M | 117.8M | 114.7M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 4.1M | 7.6M | 11.3M | 11.8M | 16.5M | 17.6M | 19.3M | 23.2M | 31.5M | 32.9M |
Total Assets | 2.2B▲ 0% | 1.83B▼ 16.5% | 1.8B▼ 1.8% | 1.67B▼ 7.0% | 1.6B▼ 4.1% | 1.79B▲ 11.4% | 1.69B▼ 5.3% | 1.15B▼ 31.8% | 1.07B▼ 7.0% | 1.05B▲ 0% |
Asset Turnover | 0.28x | 0.36x | 0.39x | 0.43x | 0.46x | 0.38x | 0.40x | 0.60x | 0.65x | 0.68x |
Asset Growth % | 5.99% | -16.51% | -1.84% | -7.05% | -4.14% | 11.43% | -5.29% | -31.8% | -6.97% | -85.04% |
Total Current Liabilities | 389.8M | 264.3M | 212.5M | 166.3M | 139.2M | 191M | 234.6M | 165.9M | 165.2M | 131.2M |
Accounts Payable | 171.2M | 169.9M | 83M | 67.6M | 56.4M | 67.9M | 56.3M | 54.3M | 55.5M | 52.3M |
Days Payables Outstanding | 227.48 | 237.24 | 102.56 | 76.11 | 56.45 | 85.49 | 69.99 | 64.66 | 57.52 | 53.06 |
Short-Term Debt | 39.8M | 0 | 0 | 0 | 0 | 6.2M | 8.6M | 9.4M | 10.2M | 21.3M |
Deferred Revenue (Current) | 144.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 134.3M | 0 | 0 | 0 | 0 | 7.1M | 108.7M | 73.3M | 0 | 57.6M |
Current Ratio | 2.98x | 2.70x | 2.53x | 2.81x | 3.07x | 3.27x | 2.08x | 2.37x | 2.15x | 2.48x |
Quick Ratio | 2.74x | 2.24x | 1.85x | 1.79x | 1.93x | 2.57x | 1.38x | 1.53x | 1.26x | 1.40x |
Cash Conversion Cycle | 14.72 | 16.49 | 163.42 | 199.78 | 167.3 | 170.67 | 210.31 | 171.1 | 149.89 | 148.18 |
Total Non-Current Liabilities | 590.7M | 271.9M | 321.9M | 250M | 193.8M | 304.7M | 221.5M | 159.8M | 130.3M | 136.8M |
Long-Term Debt | 541.1M | 247.7M | 248.1M | 180M | 130M | 226.3M | 159.4M | 125.3M | 90.3M | 117.1M |
Capital Lease Obligations | 0 | 0 | 62.6M | 53.3M | 42.8M | 32.5M | 28.3M | 24.6M | 20.4M | 63.6M |
Deferred Tax Liabilities | 17.8M | 4.4M | 0 | 5.7M | 11.9M | 25.4M | 23.8M | 5.5M | 6.1M | 18M |
Other Non-Current Liabilities | 31.8M | 19.8M | 11.2M | 11M | 9.1M | 20.5M | 10M | 4.4M | 13.5M | 14.1M |
Total Liabilities | 980.5M | 536.2M | 534.4M | 416.3M | 333M | 495.7M | 456.1M | 325.7M | 295.5M | 268M |
Total Debt | 580.9M | 247.7M | 325.4M | 248.8M | 187.5M | 277M | 209.1M | 170.2M | 129.1M | 138.4M |
Net Debt | 361.2M | -136.8M | 120.1M | 137.3M | 69M | 149.3M | 121.4M | 62.5M | 39.3M | 72.8M |
Debt / Equity | 0.48x | 0.19x | 0.26x | 0.20x | 0.15x | 0.21x | 0.17x | 0.21x | 0.17x | 0.18x |
Debt / EBITDA | 24.20x | 3.62x | 10.33x | 2.19x | 1.50x | 3.34x | 1.93x | 1.99x | - | -6.75x |
Net Debt / EBITDA | 15.05x | -2.00x | 3.81x | 1.21x | 0.55x | 1.80x | 1.12x | 0.73x | - | -3.55x |
Interest Coverage | -1.28x | 0.13x | -3.27x | -2.88x | 3.21x | 3.67x | 0.47x | -32.06x | -15.55x | -16.71x |
Total Equity | 1.22B▲ 0% | 1.3B▲ 6.7% | 1.27B▼ 2.5% | 1.26B▼ 0.7% | 1.27B▲ 1.1% | 1.29B▲ 1.6% | 1.24B▼ 4.3% | 828.5M▼ 33.0% | 778.2M▼ 6.1% | 782.1M▲ 0% |
Equity Growth % | 10.24% | 6.73% | -2.47% | -0.69% | 1.12% | 1.62% | -4.25% | -32.99% | -6.07% | -86.1% |
Book Value per Share | 25.97 | 27.48 | 26.58 | 26.29 | 26.14 | 27.30 | 26.53 | 18.01 | 16.77 | 16.86 |
Total Shareholders' Equity | 1.22B | 1.3B | 1.27B | 1.26B | 1.27B | 1.29B | 1.24B | 828.5M | 778.2M | 782.1M |
Common Stock | 500K | 500K | 500K | 500K | 500K | 500K | 500K | 500K | 500K | 500K |
Retained Earnings | -299.9M | -242.4M | -288.3M | -315.5M | -303.6M | -253.1M | -314.9M | -707M | -779.9M | -774.8M |
Treasury Stock | -4.4M | -5.3M | -8.9M | -9.8M | -21.3M | -66.8M | -85.9M | -99M | -102.3M | 0 |
Accumulated OCI | -31.3M | -33.7M | -32M | -28.1M | -33.8M | -35.8M | -27M | -44.6M | -32M | -36M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AVNS Cash Flow Statement
Avanos Medical, Inc. (AVNS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 144.2M | -145.6M | -74.5M | -2.5M | 87.3M | 90.9M | 32.4M | 100.7M | 74.7M | 49M |
Operating CF Margin % | 23.58% | -22.32% | -10.68% | -0.35% | 11.72% | 13.29% | 4.81% | 14.64% | 10.65% | - |
Operating CF Growth % | -23.62% | -200.97% | 48.83% | 96.64% | 3592% | 4.12% | -64.36% | 210.8% | -25.82% | -265.97% |
Net Income | 79.3M | 57.5M | -45.9M | -27.2M | 5.2M | 50.5M | -61.8M | -392.1M | -72.9M | -69.4M |
Depreciation & Amortization | 59.5M | 33.5M | 36.9M | 42.9M | 38.3M | 47.7M | 46.1M | 45.5M | 38.9M | 29.3M |
Stock-Based Compensation | 12.6M | 10.5M | 10.5M | 12.1M | 13.2M | 15.9M | 15.8M | 13.8M | 0 | 7.6M |
Deferred Taxes | -6.2M | 3.7M | -6.5M | 25.9M | -3.4M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.3M | -107.4M | -9.9M | 11.6M | 8M | 1.1M | 50.3M | 398.5M | 98.9M | 118.9M |
Working Capital Changes | -4.3M | -143.4M | -59.6M | -67.8M | 26M | -24.3M | -18M | 35M | 9.8M | -27.3M |
Change in Receivables | -15.3M | 67.4M | -800K | 45.8M | -10.8M | -24.7M | 39M | -6.6M | 30.9M | 5.8M |
Change in Inventory | -16.8M | -34.5M | -21.3M | -21.8M | 17.2M | -30.9M | 4.7M | 39M | 200K | -1M |
Change in Payables | 18.8M | -64M | -83.6M | -18.9M | -11.9M | 35.4M | -14.4M | -900K | 600K | 7M |
Cash from Investing | -43.1M | 639.5M | -108.1M | -24.2M | -21M | -135.4M | 21.6M | -27.5M | -60.6M | -51.5M |
Capital Expenditures | -43.2M | -49.1M | -50.6M | -20.2M | -21M | -19.3M | -17.8M | -17.8M | -31.6M | -24.9M |
CapEx % of Revenue | 7.06% | 7.53% | 7.25% | 2.83% | 2.82% | 2.82% | 2.64% | 2.59% | 4.51% | 3.48% |
Acquisitions | 100K | 688.6M | -57.5M | -4M | 0 | -116.1M | 39.4M | -9.7M | -28M | -5.3M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 100K | 754.3M | 0 | 0 | 0 | 0 | 0 | 0 | -1M | -21.3M |
Cash from Financing | 2.2M | -324.4M | 1.5M | -70M | -55.3M | 56.7M | -94.2M | -49.1M | -37M | -7.9M |
Debt Issued (Net) | 0 | -339M | -200K | -69.8M | -50M | 103.4M | -64.7M | -33.6M | -34.4M | -9.4M |
Equity Issued (Net) | -2.5M | -900K | -3.6M | -900K | -11.5M | -45.5M | -19.1M | -12.8M | -2.6M | -800K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -2.5M | -900K | -3.6M | -900K | -11.5M | -45.5M | -19.1M | -12.8M | -3.3M | -1.1M |
Other Financing | 4.7M | 15.5M | 5.3M | 700K | 6.2M | -1.2M | -10.4M | -2.7M | 0 | 2.3M |
Net Change in Cash | 106M▲ 0% | 164.8M▲ 55.5% | -179.2M▼ 208.7% | -93.8M▲ 47.7% | 7M▲ 107.5% | 9.2M▲ 31.4% | -40M▼ 534.8% | 20M▲ 150.0% | -17.9M▼ 189.5% | -31.4M▲ 0% |
Free Cash Flow | 101M▲ 0% | -194.7M▼ 292.8% | -125.1M▲ 35.7% | -22.7M▲ 81.9% | 66.3M▲ 392.1% | 71.6M▲ 8.0% | 14.6M▼ 79.6% | 82.9M▲ 467.8% | 43.1M▼ 48.0% | 24.1M▲ 0% |
FCF Margin % | 16.51% | -29.85% | -17.93% | -3.18% | 8.9% | 10.47% | 2.17% | 12.05% | 6.15% | 3.37% |
FCF Growth % | -36.76% | -292.77% | 35.75% | 81.85% | 392.07% | 7.99% | -79.61% | 467.81% | -48.01% | -78.86% |
FCF per Share | 2.16 | -4.13 | -2.63 | -0.47 | 1.36 | 1.51 | 0.31 | 1.80 | 0.93 | 0.52 |
FCF Conversion (FCF/Net Income) | 1.82x | -2.53x | 1.62x | 0.09x | 13.86x | 1.80x | -0.52x | -0.26x | -1.10x | -0.35x |
Interest Paid | 28.7M | 20.6M | 16.7M | 0 | 0 | 0 | 14.7M | 11.5M | 6.5M | 0 |
Taxes Paid | 21.4M | 96.6M | 8.4M | 0 | 0 | 0 | 23.6M | 3.3M | 14.1M | 0 |
AVNS Key Ratios
Avanos Medical, Inc. (AVNS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 6.84% | 4.58% | -3.58% | -2.16% | 0.5% | 3.94% | -4.89% | -37.98% | -8.45% | -8.91% |
Return on Invested Capital (ROIC) | -0.76% | 1.91% | -0.32% | 3.83% | 4.76% | 2.26% | 3.48% | 2.67% | -5.41% | -5.39% |
Gross Margin | 55.08% | 59.93% | 57.65% | 54.64% | 51.02% | 57.62% | 56.39% | 55.44% | 49.77% | 49.36% |
Net Margin | 12.97% | 8.82% | -6.58% | -3.81% | 0.85% | 7.38% | -9.18% | -57.01% | -9.68% | -9.69% |
Debt / Equity | 0.48x | 0.19x | 0.26x | 0.20x | 0.15x | 0.21x | 0.17x | 0.21x | 0.17x | 0.18x |
Interest Coverage | -1.28x | 0.13x | -3.27x | -2.88x | 3.21x | 3.67x | 0.47x | -32.06x | -15.55x | -16.71x |
FCF Conversion | 1.82x | -2.53x | 1.62x | 0.09x | 13.86x | 1.80x | -0.52x | -0.26x | -1.10x | -0.35x |
Revenue Growth | 8.02% | 6.65% | 6.94% | 2.47% | 4.17% | -8.13% | -1.58% | 2.15% | 1.95% | 3.87% |
Related:AVNS Dividend History·AVNS Revenue History·AVNS Price History·AVNS P/E History·AVNS Financial Ratios·AVNS Institutional Holders
AVNS SEC Filings & Documents
Avanos Medical, Inc. (AVNS) SEC filings — annual & quarterly reports (10-K, 10-Q)
AVNS Frequently Asked Questions
Avanos Medical, Inc. (AVNS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Avanos Medical, Inc. (AVNS) reported $715.9M in revenue for fiscal year 2025. This represents a 57% decrease from $1.68B in 2012.
Avanos Medical, Inc. (AVNS) grew revenue by 1.9% over the past year. Growth has been modest.
Avanos Medical, Inc. (AVNS) reported a net loss of $69.4M for fiscal year 2025.
Dividend & Returns
Avanos Medical, Inc. (AVNS) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.
Avanos Medical, Inc. (AVNS) generated $24.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.